Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum
10 Outubro 2023 - 8:00AM
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal
solutions company, celebrated twenty years of the NuVasive XLIF
procedure at the Society for Minimally Invasive Spine Surgery
(SMISS) ’23 Annual Forum.
“Very few medical technology innovations have transformed an
industry like the NuVasive XLIF procedure. Twenty years of XLIF has
produced two decades of unmatched clinical validation, represented
by an incredible body of evidence on the reproducibility, safety,
and efficacy of the procedure,”1-4 said Kyle Malone, senior
vice president, Scientific Affairs of Globus Medical. “We have a
true legacy to carry on as Globus Medical, and the focus on
procedural innovation, surgeon partnership, research, and education
that contributed to the success of XLIF will continue to guide
future innovation while changing the lives of more patients around
the globe.”
More than 120 surgeons and industry leaders gathered at SMISS to
celebrate the XLIF procedure. Hosted by NuVasive, the evening event
featured more than 20 surgeon speakers discussing the past, present
and future impact of the procedure.
Dr. Frank Phillips, Rush University Medical Center, has been an
XLIF user since 2003. “XLIF has been one of the most disruptive
approaches to emerge in the spine field.” This surgical technique
and its procedurally integrated portfolio of access, interbody
implants, fixation and enabling technologies continue to
demonstrate more predictable outcomes than traditional spinal
fusion procedures, with substantially fewer complications.5-9
“It’s remarkable how XLIF has continued to advance lateral,
minimally invasive surgical applications,” said Dr. Bill Smith,
neurosurgeon and early XLIF adopter who has completed over 1,800
XLIF procedures. “From its evolution of a one-level degenerative
procedure to becoming the standard of care across multiple
pathologies, XLIF has advanced patient care in historically
challenging complex, deformity, tumor and trauma cases.”
With ~300,000 procedures performed, 200+ educational courses
hosted, 600+ peer-reviewed publications, and 60+ dedicated products
launched, XLIF continues to change patient lives.
“I look at what XLIF has done for minimally invasive surgery and
single-position surgery, and I can only imagine what the future of
innovation holds for the next twenty years in lateral,” said Dr. J.
Alex Thomas, Atlantic Brain and Spine.
Learn more about the past, present and future of the XLIF
procedure here.
- Sembrano JN, Tohmeh
A, Isaacs R, et al. Two-year comparative outcomes of MIS lateral
and MIS transforaminal interbody fusion in the treatment of
degenerative spondylolisthesis: part I: clinical findings. Spine
2016;41(Suppl 8):S123-S132.
- Lehmen JA, Gerber
EJ. MIS lateral spine surgery: A systematic literature review of
complications, outcomes, and economics. Eur Spine J 2015;24(Suppl
3):287-313.
- Rihn JA, Patel R,
Makda J, et al. Complications associated with single-level
transforaminal lumbar interbody fusion. Spine J
2009;9(8):623-9.
- Lucio JC, VanConia
RB, Deluzio KJ, et al. Economics of less invasive spinal surgery:
an analysis of hospital cost differences between open and minimally
invasive instrumented spinal fusion procedures during the
perioperative period. Risk Management and Healthcare Policy
2012;5:65-74.
- Lehmen JA, Gerber EJ. MIS lateral spine surgery: A systematic
literature review of complications, outcomes, and economics. Eur
Spine J 2015;24(Suppl 3):287-313.
- Cheng I, Briseno MR, Arrigo RT, et al. Outcomes of two
different techniques using the lateral approach for lumbar
interbody arthrodesis. Global Spine J 2015;5(4):308-14.
- Khajavi K, Shen A, Lagina M, et al. Comparison of clinical
outcomes following minimally invasive lateral interbody fusion
stratified by preoperative diagnosis. Eur Spine J 2015;24(Suppl
3):322-30.
- Okuda S, Miyauchi A, Oda T, et al. Surgical complications of
posterior lumbar interbody fusion with total facetectomy in 251
patients. J Neurosurg Spine 2006;4(4):304-9.
- Scaduto AA, Gamradt SC, Yu WD, et al. Perioperative
complications of threaded cylindrical lumbar interbody fusion
devices: anterior versus posterior approach. J Spinal Disord Tech
2003;16(6):502-7.
About Globus Medical, Inc.Globus Medical is
committed to providing innovative technologies and industry-leading
clinical support to help surgeons and healthcare providers deliver
better care around the globe. The Company provides one of the most
comprehensive offerings of musculoskeletal solutions and enabling
technologies to impact the care continuum, now including the
procedurally integrated portfolio of NuVasive. The Company’s
employees are relentlessly focused on advancing patient care. For
more information, please visit www.globusmedical.com/uniting.
Safe Harbor Statements
All statements included in this press release other than
statements of historical fact are forward-looking statements and
may be identified by their use of words such as “believe,” “may,”
“might,” “could,” “will,” “aim,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “plan” and other similar terms.
These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and
trends. Forward-looking statements are only predictions and are
subject to many risks, uncertainties and other factors that may
affect our businesses and operations and could cause actual results
to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, the risks and
costs associated with the integration of, and the ability of Globus
Medical and NuVasive to integrate, their businesses successfully
and to achieve anticipated synergies, health epidemics, pandemics
and similar outbreaks, including the COVID-19
pandemic, factors affecting our quarterly results, our ability
to manage our growth, our ability to sustain
our profitability, demand for our products, our ability to
compete successfully (including without limitation our ability to
convince surgeons to use our products and our ability to attract
and retain sales and other personnel), our ability to rapidly
develop and introduce new products, our ability to develop and
execute on successful business strategies, our ability to comply
with laws and regulations that are or may
become applicable to our businesses, our ability to safeguard
our intellectual property, our success in defending legal
proceedings brought against us, trends in the medical device
industry, general economic conditions, and other risks. For a
discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our most recent annual report on Form 10-K
filed with the Securities and Exchange Commission, including the
sections labeled “Risk Factors” and “Cautionary Note Concerning
Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and
other filings with the Securities and Exchange Commission. These
documents are available at www.sec.gov. Moreover, we operate
in an evolving environment. New risk factors and uncertainties
emerge from time to time and it is not possible for us to predict
all risk factors and uncertainties, nor can we assess the impact of
all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statements as
a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Investor contact:Brian
Kearns610-930-1800investors@globusmedical.com
Media contact:Melanie
Ordoñez858-722-3899media@globusmedical.com
Globus Medical (NYSE:GMED)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Globus Medical (NYSE:GMED)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024